argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.

Employees

1,599

Sector

Biotechnology & Medical Research

Calendar

Jul. 31 - Q2 2025 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
25-07-11	480.50 €	-1.01%	73,198
25-07-10	485.40 €	+4.39%	76,016
25-07-09	465.00 €	+0.19%	106,140
25-07-08	464.10 €	-0.39%	80,099
25-07-07	465.90 €	-0.26%	56,141

Real-time Euronext Bruxelles, July 11, 2025 at 11:55 am EDT

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG MSCI

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

480.50EUR

Average target price

664.70EUR

Spread / Average Target

+38.34%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Euronext Bruxelles Other stock markets 11:55:00 2025-07-11 am EDT			5-day change	1st Jan Change
480.50 ^EUR	-1.01%		+2.87%	-19.92%

Jul. 08	Deutsche Bank Upgrades Argenx to Buy, Raises PT	MT
Jul. 08	European shares flat as investors assess new US tariff proposals	RE

Capitalization	29.41B 34.37B 27.37B 25.48B 47.04B 2,949B 52.23B 329B 125B 1,381B 129B 126B 5,067B	P/E ratio 2025 *	49.2x	P/E ratio 2026 *	27.7x
Enterprise value	26.47B 30.94B 24.64B 22.94B 42.35B 2,655B 47.02B 296B 113B 1,243B 116B 114B 4,562B	EV / Sales 2025 *	8.36x	EV / Sales 2026 *	6.18x
Free-Float	99.23%	Yield 2025 *	-	Yield 2026 *	-

Deutsche Bank Upgrades Argenx to Buy, Raises PT	Jul. 08	MT
European shares flat as investors assess new US tariff proposals	Jul. 08	RE
Unnatural Products, Inc. Announces Multi-Target Collaboration with argenx to Develop Oral Macrocyclic Peptide Therapeutics	Jul. 01	CI
Argenx to Move ARGX-119 Development to Registrational Study of Congenital Myasthenic Syndromes	Jun. 30	MT
Argenx SE Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes	Jun. 30	CI
Argenx Obtains Approval in EU for Monotherapy for Rare Autoimmune Disease	Jun. 22	MT
Sector Update: Health Care Stocks Softer in Afternoon Trading	Jun. 20	MT
Argenx SE Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy	Jun. 20	CI
Argenx Receives European Commission Approval for Monotherapy to Treat Neuromuscular Disorder	Jun. 20	MT
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	Jun. 16	MT
Argenx Says Vyvgart Improved Muscle Strength in Phase 2 Myositis Trial	Jun. 11	MT
Argenx SE Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease	Jun. 11	CI
Argenx Presents New Data Highlighting Phase 2 Results In Myositis And Sjogren'S Disease	Jun. 10	RE

Deutsche Bank Upgrades Argenx to Buy, Raises PT	Jul. 08	MT
Baird Upgrades argenx to Outperform From Neutral, Price Target is $680	May. 13	MT
Bernstein Upgrades argenx to Outperform, Boosts PT	Mar. 17	MT
Wedbush Raises Argenx's Price Target to $665 From $655, Maintains Outperform Rating	Dec. 27	MT
Oppenheimer Adjusts argenx SE ADR Price Target to $675 From $646, Maintains Outperform Rating	Nov. 21	MT

argenx SE Stock

Equities

ARGX

NL0010832176

Biotechnology & Medical Research

Valuation: argenx SE

Chart: argenx SE

Latest news: argenx SE

Last Transcript: argenx SE

Analysts' recommendations: argenx SE

Press Releases: argenx SE

News in other languages: argenx SE

Quotes and Performance

Course Extremes

Managers and Directors: argenx SE

ETFs: argenx SE

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Argenx : argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes	Jun. 30	PU
Argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes	Jun. 30	GL
Argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes	Jun. 30	AQ
Argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy	Jun. 20	GL
Argenx : argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy	Jun. 19	PU

Succesvolle IPO EnergyVision op lichtgroene beurs	Jul. 09
Faute de carotte, le bâton fait son retour	Jul. 08
Avis d'analystes du jour : nouveaux suivis sur Accor et Galderma, ArgenX relevé et Arkema dégradé	Jul. 08
Deutsche Bank zet Argenx op de kooplijst	Jul. 08
Umicore smaakmaker in Brussel	Jul. 06

1 day	-1.01%
1 week	+4.37%
Current month	+2.28%
1 month	-5.41%
3 months	-1.58%
6 months	-25.39%
Current year	-19.92%

1 week	456.7	486.4
1 month	456.6	509.8
Current year	456.6	658
1 year	419.8	658
3 years	271	658
5 years	180.1	658
10 years	8.46	658

Manager	Title	Age	Since
Tim van Hauwermeiren CEO	Chief Executive Officer	53	2008-07-14
Karl Gubitz DFI	Director of Finance/CFO	55	2021-05-31
Filip Borgions CTO	Chief Tech/Sci/R&D Officer	-	2014-12-31

Director	Title	Age	Since
Tim van Hauwermeiren BRD	Director/Board Member	53	2014-06-30
Peter K. M. Verhaeghe CHM	Chairman	67	2008-10-14
Joseph deBethizy BRD	Director/Board Member	75	2015-05-12

Name	Weight	AuM	1st Jan change
HAN-GINS TECH MEGATREND EQUAL WEIGHT UCITS ETF - USD	0.93%	80 M€	+2.68%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	0.46%	21 M€	+4.23%	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ARGENX SE	-1.01%	+4.37%	+11.64%	+37.92%	34.72B
BIONTECH SE	-0.90%	+2.63%	+38.86%	-33.64%	28.05B
WUXI APPTEC CO., LTD.	+9.99%	+9.09%	+105.51%	-29.99%	28B
SUMMIT THERAPEUTICS INC.	-3.40%	+1.83%	+201.57%	+2,350.98%	19.22B
INSMED INCORPORATED	+1.57%	+0.39%	+34.31%	+295.89%	18.36B
GENMAB A/S	-1.18%	+6.66%	-21.93%	-44.75%	13.43B
WUXI BIOLOGICS (CAYMAN) INC.	+3.70%	+3.29%	+150.00%	-66.69%	13.32B
AKESO, INC.	+4.52%	+6.69%	+203.08%	+361.10%	12.38B
EXELIXIS, INC.	-0.69%	-2.80%	+103.45%	+103.82%	12.32B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.25%	-2.69%	+156.22%	-	9.78B
Average	+1.38%	+4.70%	+98.27%	+330.51%	18.96B
Weighted average by Cap.	+1.46%	+5.14%	+84.25%	+302.62%

	2025 *	2026 *
Net sales	3.17B 3.7B 2.95B 2.74B 5.07B 318B 5.62B 35.4B 13.48B 149B 13.88B 13.59B 546B	4.1B 4.8B 3.82B 3.56B 6.57B 412B 7.29B 45.88B 17.48B 193B 17.99B 17.62B 707B
Net income	714M 835M 665M 619M 1.14B 71.63B 1.27B 7.98B 3.04B 33.54B 3.13B 3.07B 123B	1.16B 1.36B 1.08B 1.01B 1.86B 116B 2.06B 12.97B 4.94B 54.5B 5.09B 4.98B 200B
Net Debt	-2.93B -3.43B -2.73B -2.54B -4.69B -294B -5.21B -32.78B -12.48B -138B -12.85B -12.59B -505B	-4.05B -4.73B -3.77B -3.51B -6.48B -406B -7.19B -45.25B -17.23B -190B -17.74B -17.37B -697B